BioNotebook: Controversial StemCells board appointment; Portola/Daiichi Sankyo, Lexicon/JDRF, Supernus; and stock offerings

 
• By Mandy Jackson

StemCells appoints former CIRM president; Daiichi Sankyo, Portola collaborate with Factor Xa inhibitor; Lexicon, JDRF partner on Phase II study; Supernus signs royalty deal; and Bluebird, Ultragenyx, Auspex and Ocera price offerings.

More from Alimentary/Metabolic

More from Therapy Areas